FF301 致：香港交易及結算所有限公司 公司名稱: 樂普心泰醫療科技（上海）股份有限公司 (「本公司」) 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02291 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 346,749,997 | RMB | | 1 RMB | | 346,749,997 | 本月底法定/註冊股本總額： RMB 346,749,997 備註： 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2 ...

Core Viewpoint - The stock of HeartTech Medical (2291.HK) experienced a significant increase, reaching a high of 27.4 HKD, marking a 30% rise over the past month, with a total market capitalization of 9.3 billion HKD [1] Company Summary - HeartTech Medical is recognized as a leading manufacturer of congenital heart disease occluders in China, holding a market share of 38% based on sales revenue in 2021 [1] - The company is characterized as a stable and profitable innovative medical device enterprise listed in Hong Kong [1] Industry Summary - The National Healthcare Security Administration has introduced a new pricing mechanism for newly launched drugs, adding over 100 price items related to new medical technologies to promote the clinical application of high-end medical devices [1] - According to CITIC Securities, the overall innovation capability of Hong Kong's medical device companies is strong, with many firms approaching profitability or experiencing rapid performance releases [1] - The medical device sector has seen significant stock price increases this year, with some companies doubling in value due to new product launches, technological breakthroughs, and strong cash positions [1]

Group 1 - The article provides a list of companies listed on the Hong Kong stock market along with their dividend distribution dates and shareholder meeting dates [1][4][5] - Notable companies mentioned include China Railway, Green Town China, and Budweiser APAC, which are scheduled for dividend payments [4][5] - The document outlines various companies' actions regarding capital increases and dividend distributions, indicating ongoing corporate activities in the market [4][5]

[Company Announcement: Proposed Appointment of Supervisor and Supplemental Announcement Regarding Annual Reports](index=1&type=section&id=%E5%85%AC%E5%8F%B8%E5%85%AC%E5%91%8A%EF%BC%9A%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B%E5%8F%8A%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) This announcement details the proposed appointment of a new supervisor and clarifies supervisor remuneration in annual reports [Proposed Appointment of Supervisor](index=1&type=section&id=%E5%BB%BA%E8%AD%B0%E5%A7%94%E4%BB%BB%E7%9B%A3%E4%BA%8B) The company proposes Ms. Wang Yong as shareholder representative supervisor and chairperson, pending shareholder approval - The company's board of supervisors recommends appointing Ms. Wang Yong as a supervisor and chairperson of the second board of supervisors[3](index=3&type=chunk) - This appointment is subject to approval by an ordinary resolution at the general meeting of shareholders[3](index=3&type=chunk)[8](index=8&type=chunk) - As a shareholder representative supervisor, Ms. Wang will not receive any remuneration from the company[7](index=7&type=chunk) [Supervisor Candidate Background: Ms. Wang Yong](index=1&type=section&id=%E7%9B%A3%E4%BA%8B%E5%80%99%E9%81%B8%E4%BA%BA%E7%9A%84%E8%83%8C%E6%99%AF) Ms. Wang Yong, 52, CFO of Lepu Medical, possesses CPA qualifications and audit experience Key Background Information | Item | Content | | :--- | :--- | | Age | 52 | | Nationality | China | | Current Key Positions | CFO, Senior Deputy General Manager at Lepu Medical (Controlling Shareholder, 300003.SZ) | | Past Key Experience | Senior Audit Manager, Audit Department, PwC Zhong Tian CPAs Beijing Branch (1996-2007) | | Professional Qualifications | Certified Public Accountant (obtained 2001) | Shareholding Information | Company Held | Capacity | Shares/Percentage | | :--- | :--- | :--- | | The Company | Via Employee Stock Ownership Platform | 147,221 shares (approx. 0.04%) | | Lepu Medical | Beneficial Owner | 191,700 shares (approx. 0.01%) | | Beijing Lepu Diagnostics | Via Employee Stock Ownership Platform | 383,955 shares (approx. 0.10%) | - Ms. Wang holds director or supervisor positions in several affiliated or non-affiliated companies, including Sichuan Ruijian Medical, Shanghai Lepu Yunzhi, and Sino-American Huashitong[4](index=4&type=chunk) [Supplemental Announcement Regarding Annual Reports](index=3&type=section&id=%E6%9C%89%E9%97%9C%E5%B9%B4%E5%A0%B1%E4%B9%8B%E8%A3%9C%E5%85%85%E5%85%AC%E5%91%8A) The company clarifies that total remuneration paid to all supervisors for fiscal years 2022-2024 was zero - This announcement provides supplementary information for the company's 2022, 2023, and 2024 annual reports[9](index=9&type=chunk) Total Remuneration Paid to All Supervisors | Fiscal Year | Total Remuneration Paid to All Supervisors | | :--- | :--- | | 2022 | Zero | | 2023 | Zero | | 2024 | Zero | - The disclosed total remuneration of zero covers all items, including fees, basic salary, housing allowances, in-kind benefits, and bonuses[9](index=9&type=chunk)

Group 1 - The medical and pharmaceutical sector continues to perform strongly, with the Hong Kong medical ETF (159366) rising over 2% in early trading, marking a three-day increase [1] - Key stocks such as Kelaiying, Micron Medical, and Zhaoyan Pharmaceutical saw significant gains of 5.90%, 5.47%, and 4.73% respectively, contributing to a cumulative increase of 6.32% in the ETF over the past week [1] - A major policy announcement from the Central Committee and the State Council aims to improve public welfare and healthcare, including the establishment of a drug catalog adjustment mechanism and the promotion of quality healthcare resource sharing [1] Group 2 - Dongwu Securities highlights three factors that suggest 2025 will be a pivotal year for innovative drugs, including the orderly rollout of significant business development (BD) deals, expected profitability for more companies by 2026, and an improving domestic environment for innovative drugs [2] - The Chinese innovative drug market is poised for rapid growth, supported by favorable policies and international expansion, making it a highly promising sub-sector within the pharmaceutical industry [2] - The Hong Kong medical ETF (159366) focuses on unique medical segment leaders, including internet healthcare, CXO, and medical devices, and operates as a pure Hong Kong Stock Connect ETF with T+0 trading support [2]

Core Viewpoint - The article highlights the successful commercialization and clinical application of the ScienCrown transcatheter aortic valve replacement (TAVR) system developed by Lepu Medical Technology, marking a significant advancement in the treatment of aortic stenosis patients in China [2][5][10]. Company Overview - Lepu Medical Technology (Shanghai) Co., Ltd. is a leading innovator in the field of interventional medical devices for structural heart diseases, supported by the Shanghai Biomedical Investment Fund. The company went public on November 8, 2022, on the Hong Kong Stock Exchange under the stock code 02291.HK [17]. - The company focuses on the research, development, production, and marketing of interventional medical devices, with over 40 products listed and in development, covering congenital heart disease, stroke prevention, and valve treatment solutions [17]. Product Introduction - The ScienCrown TAVR system is the world's first and only self-expanding short valve product with balloon-expandable advantages, designed to address existing challenges in TAVR procedures [4][12]. - The product features 100% full release and retrieval capabilities, dual access routes, and innovative designs that significantly enhance clinical practice [4][12][15]. Clinical Application - The first commercial implantations of the ScienCrown valve have been successfully conducted in multiple clinical centers across China, demonstrating its effectiveness and safety [5][7]. - Clinical trial results indicate a procedural success rate of approximately 99.2% and a device success rate of about 98.4%, with low rates of paravalvular leak and no severe leaks reported [7][10]. Market Context - Aortic valve disease, particularly aortic stenosis (AS), is a common cardiovascular issue, especially among the elderly, with a prevalence of approximately 11.5% in patients over 60 years old [8][10]. - The number of patients with aortic stenosis and aortic regurgitation in China is projected to reach 9.3 million by 2025, with a compound annual growth rate of 2.6% from 2022 to 2025 [10].

Group 1: Hong Kong Stock Market Performance - The Hang Seng Index rose by 1.36%, gaining 297 points to close at 22,206 points, while the Hang Seng Tech Index increased by 1.87% [1] - The early trading volume in the Hong Kong stock market reached HKD 116.4 billion [1] Group 2: Real Estate Sector - Foreign institutions are optimistic about the recovery of the Chinese real estate sector, with Citigroup strategists urging investors to increase their holdings in Chinese real estate stocks due to expected improvements in profitability from policy support and better management practices [1] - Kwan Hung Holdings surged over 43%, while other notable gains included Rongxin China up 17%, Greentown China up 5%, CIFI Holdings up 7.88%, Sunac China up 4.22%, and Longfor Group up 6.74% [1] Group 3: AI Medical Sector - AI medical concept stocks saw an uptick as seven departments jointly promoted AI empowerment across the pharmaceutical industry, with institutions optimistic about the accelerated trend in the AI medical industry [1] - Notable stock performances included iFlytek Medical Technology up 7.2%, Yidu Tech up 5.35%, Crystal Tech Holdings up 4.69%, and MicroPort Scientific up 4.07% [1] Group 4: Other Notable Stocks - Horizon Robotics rose over 7% following a strategic partnership with Bosch to develop an upgraded version of Bosch's advanced driver assistance system [2] - KPB Medical surged over 14%, with a cumulative increase of over 95% this week after its core product was approved for sale in China [3] - Xintai Medical increased by 3.88%, although the company indicated uncertainty regarding its sales growth targets [4] - Minmetals Resources rose over 5%, reporting a 76% year-on-year increase in copper production for the first quarter, with potential adjustments to production guidance [5] - Beike-W increased by 4.88%, as the real estate fundamentals became clearer, with institutions suggesting its stock price is entering a value range [6] - Global New Materials International saw a sharp rise of over 20% before settling at a 4% increase after acquiring Merck's global performance solutions business [7]

Group 1 - The Hong Kong stock market showed strength on April 25, with the Hang Seng Healthcare Index initially rising before retreating, and the Hang Seng Healthcare Index ETF (159557) increasing by over 1%, leading in gains among similar ETFs, with a premium trading rate of 0.61% [1] - Key stocks in the healthcare sector included Xintai Medical, which rose over 6%, Jingtai Holdings, which increased over 5%, and iFlytek Medical Technology, which gained over 4% [1] - A new policy from the Ministry of Industry and Information Technology and six other departments was announced on April 24, outlining the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", with significant goals set for 2027 and 2030 regarding technological advancements and digital transformation in the pharmaceutical sector [1] Group 2 - Guolian Minsheng Securities identified two core investment themes for the pharmaceutical sector in 2025: 1) High-quality innovative drugs going overseas, as domestic IND products are well-positioned for international markets; 2) Valuation recovery of left-side assets, focusing on sectors like CXO, consumer healthcare, and pharmacies that have seen significant pullbacks [2] - Huaxin Securities noted that the market is entering a period of consolidation, with potential challenges from simultaneous withdrawals of southbound and foreign capital, but maintains a bullish outlook for the medium term, emphasizing opportunities in the core technology sector and the long-term potential of the innovative drug industry post-policy adjustments [2]

港股心泰医疗(02291.HK)快速拉升，一度涨近29%，成交超8000万港元。 ...

Group 1 - The Hang Seng Index opened with a gain of 2.4% [1] - The Hang Seng Tech Index opened with a gain of 3.5% [1] - HeartTech Medical (02291.HK) surged 8.28% after resuming trading [1] Group 2 - Pop Mart (09992.HK) opened with a gain of 4.6% and announced a year-on-year revenue growth of 165%-170% for Q1 2025 [1]